NCT02452424 - A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 2, 2015

Primary Completion Date

August 17, 2018

Study Completion Date

October 12, 2018

Conditions

MelanomaNon-small Cell Lung CancerSquamous Cell Carcinoma of the Head and NeckGastrointestinal Stromal Tumor (GIST)Ovarian Cancer

Interventions

DRUG

PLX3397

PLX3397 capsules, 200 mg

BIOLOGICAL

Pembrolizumab

Pembrolizumab, 200 mg, IV

Trial Locations (12)

Memorial Sloan Kettering Cancer Center, New York

Medical University Health Hollings Cancer Center, Charleston

Vanderbilt Ingram Cancer Center, Nashville

Karmanos Cancer Institute, Detroit

Washington University St. Louis Siteman Cancer Center, St Louis

South Texas Accelerated Research Therapeutics, San Antonio

HonorHealth Research Institute, Scottsdale

Ronald Reagan UCLA Medical Center, Los Angeles

Marin Cancer Care, Greenbrae

Massachusetts General Hospital, Boston

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston